Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject or subjects legally authorized guardian(s) must provide signed, informed consent prior to performing any trial-related activities~* The subject and his/her guardian(s) must have the ability to comply with the protocol~* The subject must have a confirmed diagnosis of alpha-Mannosidosis as defined by alpha-Mannosidase activity \< 10% of normal activity (historical data)~* The subject must have an age at the time of screening ≥ 5 years and ≤ 35 years~* The subject must have the ability to physically and mentally cooperate in the tests~* The subject must have an ECHO without abnormalities that, in the opinion of the Investigator, would preclude participation in the trial~Exclusion Criteria:~* The subjects diagnosis cannot be confirmed by alpha-Mannosidase activity \< 10% of normal activity~* The subject cannot walk without support~* Presence of known chromosomal abnormality and syndromes affecting psychomotor development, other than alpha-Mannosidosis~* History of BMT~* Presence of known clinically significant cardiovascular, hepatic, pulmonary, or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial~* Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial~* Pregnancy: Pregnant woman is excluded. Before start of the treatment the investigators will for women of childbearing potential perform a pregnancy test and decide whether or not there is a need for contraception~* Psychosis; any psychotic disease, also in remission, is an exclusion criteria~* Planned major surgery that, in the opinion of the Investigator, would preclude participation in the trial~* Participation in other interventional trials testing IMP (including Lamazym) within the last 3 months~* Adult patients who, in the opinion of the Investigator, would be unable to give consent, and who does not have any legal protection or guardianship~* Total IgE \>800 IU/ml~* Known allergy to the IMP or any excipients (Sodium-Phosphate, Glycine, Mannitol)

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Lamazym (Type: ACTIVE_COMPARATOR): 1 mg Lamazym/kg body weight
- Placebo (Type: PLACEBO_COMPARATOR): Placebo is formulated as an isotonic phosphate buffer with glycine and mannitol

Based on this trial design, predict the completion outcome and termination type (if applicable).